OvaScience is a biotechnology startup that aims to revolutionize the field of in vitro fertilization (IVF) by enhancing egg quality through innovative science. The company's proprietary technology, licensed from Harvard Medical School and Massachusetts General Hospital, harnesses a woman's cellular energy to improve the quality of eggs. Co-founded by Richard Aldrich, Michelle Dipp, M.D., Ph.D., and Christoph Westphal, M.D., Ph.D. of Longwood Founders Fund, along with fertility expert Jonathan Tilly, Ph.D. of Massachusetts General Hospital, and aging expert David Sinclair, Ph.D. of Harvard Medical School, OvaScience is supported by leading life science investors Longwood Founders Fund and Bessemer Venture Partners.
Founded in 2011, OvaScience operates in the Biotechnology and Health Care industries. The company received a significant $53.80M post-IPO equity investment on 01 June 2016. OvaScience boasts a world-class team of top reproductive endocrinologists, embryologists, scientists, and advisors dedicated to bringing this groundbreaking technology to patients.
